1. Chancellor JV, Hill AM, Sabin CA, Simpson KN, Youle M. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics (in press).
2. Prognosis in HIV-1 infection predicted by the quantity of virus in the plasma;Mellors;Science,1996
3. Anis-Aslam H, Hogg RS, Wang X, et al. The effect of attenuating CD4 decline on subsequent hospitalization: potenital benefit of viral load driven antiretroviral therapy. 4th Conference on Retroviruses and Opportunistic Infections, Washington, January 22–26, 1997: 263 (abstr).
4. Myers MW, Montaner JSG, the INCAS study group. A randomized, double-blind trial of the effects of zidovudine, didanosine, and nevirapine combinations in antiviral naïve, AIDS-free, HIV-infected patients with CD4 counts 200–600/mm3. XIth international Conference on AIDS, Vancouver, 1996: ThB934 (abstr).